Life Sciences IP Due Diligence: Implications of Recent Decisions, Legislation, PTO Guidance on Diligence Analysis
Recording of a 90-minute premium CLE webinar with Q&A
This CLE webinar will guide counsel for conducting intellectual property due diligence in life sciences deals. The panel will discuss recent court decisions as well as current and pending legislation relating to patent rights that impact life sciences analyses. The panel will offer steps companies and counsel should take to adapt the due diligence analysis.
Outline
- Recent cases
- Current and pending legislation
- USPTO guidance
- Best practices for life sciences IP due diligence
Benefits
The panel will review these and other relevant issues:
- What are the best approaches for counsel to identify the IP assets to review during due diligence?
- What implications do recent court decisions have on the IP due diligence process in the life sciences?
- How should counsel address IP ownership questions that arise during due diligence?
Faculty
Thomas L. Irving
Partner
Finnegan Henderson Farabow Garrett & Dunner
Mr. Irving has 35 years of experience in the field of IP law. His practice includes due diligence, patent prosecution,... | Read More
Mr. Irving has 35 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. He has served as lead counsel in many patent interferences.
Close
Sherry M. Knowles
Principal
Knowles IP Strategies
Ms. Knowles provides global guidance on complex IP matters, patent litigation strategy and assistance, licensing,... | Read More
Ms. Knowles provides global guidance on complex IP matters, patent litigation strategy and assistance, licensing, patent prosecution, opinions, obtaining and protecting the full value of innovation, investor support and monetization of assets. She is an intellectual property attorney with 30 years of experience in global corporate and private practice. She has acted as an expert witness on licensing matters in several disputes involving large pharmaceutical companies. From 2006-2010, she was the Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, where she served as the worldwide head of patents for all litigation and transactional matters.
Close
Hilary J. Libka
Chief IP Counsel
Dana-Farber Cancer Institute
Ms. Libka manages Dana-Farber’s extensive worldwide patent, trademark, and copyright portfolio. She advises... | Read More
Ms. Libka manages Dana-Farber’s extensive worldwide patent, trademark, and copyright portfolio. She advises senior management, administration, and faculty members on issues of intellectual property policy, procurement/ownership, and protection/enforcement. She also handles intellectual property controversies and negotiates collaboration, commercialization, and settlement terms. She facilitated a $25-million royalty monetization of licensed Dana-Farber technology, helped create a new $80-million research center at the Institute, and contributed to litigation successfully recognizing a Dana-Farber researcher as an inventor on six groundbreaking immunotherapy patents.
Close
Ryan Murphey
Counsel
Ropes & Gray
Mr. Murphey advises clients on intellectual property issues in connection with transactions, including mergers and... | Read More
Mr. Murphey advises clients on intellectual property issues in connection with transactions, including mergers and acquisitions, in- and out-licensing relationships, and venture financings. He evaluates the intellectual property portfolios of target companies, as well as potentially blocking third-party intellectual property. He works with clients in the biotechnology and biopharmaceutical industries on a wide range of intellectual property issues, including patent portfolio strategy, patent opinions, and freedom-to-operate analysis.
Close